Share This Page
Epinephrine; procaine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for epinephrine; procaine hydrochloride and what is the scope of freedom to operate?
Epinephrine; procaine hydrochloride
is the generic ingredient in one branded drug marketed by Bel Mar and is included in two NDAs. Additional information is available in the individual branded drug profile pages.Summary for epinephrine; procaine hydrochloride
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| DailyMed Link: | epinephrine; procaine hydrochloride at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for epinephrine; procaine hydrochloride
US Patents and Regulatory Information for epinephrine; procaine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bel Mar | PROCAINE HYDROCHLORIDE W/ EPINEPHRINE | epinephrine; procaine hydrochloride | INJECTABLE;INJECTION | 080759-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bel Mar | PROCAINE HYDROCHLORIDE W/ EPINEPHRINE | epinephrine; procaine hydrochloride | INJECTABLE;INJECTION | 080758-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Epinephrine and Procaine Hydrochloride Market Dynamics, Patent Risk, and Financial Trajectory
Epinephrine and procaine hydrochloride occupy different commercial positions. Epinephrine is a high-volume, strategically important emergency medicine with branded auto-injector economics, recurring shortages, device complexity, and meaningful payer sensitivity. Procaine hydrochloride is an older local anesthetic with limited modern demand, largely generic competition, and minimal patent-based exclusivity.
Epinephrine has stronger commercial growth prospects, but its value is concentrated in delivery systems, supply reliability, regulatory execution, and market access rather than in the active ingredient. Procaine hydrochloride has little remaining patent value and a declining or specialized-use financial profile.
What is the current FDA regulatory status of epinephrine and procaine hydrochloride?
Epinephrine is FDA-approved in multiple dosage forms, including injectable solutions, auto-injectors, prefilled syringes, and emergency-use products. The principal commercial categories are:
- Epinephrine auto-injectors for anaphylaxis.
- Single-dose and multidose injectable solutions for emergency medicine.
- Prefilled syringes used in hospitals and emergency response.
- Ophthalmic and specialized formulations in narrower indications.
The EpiPen epinephrine auto-injector was approved under NDA 019430. Generic epinephrine auto-injectors have subsequently entered the U.S. market, including products associated with Teva Pharmaceuticals and other manufacturers. Auvi-Q, marketed by Kaleo, is another FDA-approved epinephrine auto-injector with a voice-guided electronic delivery system. FDA approval of generic and alternative auto-injectors has expanded consumer choice while preserving device, manufacturing, and supply-chain barriers. (U.S. Food and Drug Administration [FDA], 2024a)
Procaine hydrochloride is an FDA-recognized local anesthetic active ingredient used by injection. Current commercial availability is concentrated in generic injectable products, particularly for infiltration, peripheral nerve block, and related local anesthesia applications. Demand is narrower than for lidocaine, bupivacaine, or newer long-acting local anesthetics. Many procaine products are marketed through abbreviated new drug applications or legacy injectable pathways rather than through a large branded-NDA market.
What patents protect epinephrine products?
The epinephrine molecule is long off patent. Commercial protection has historically focused on delivery systems, cartridge construction, dose control, needle mechanisms, formulation stability, and user-interface features.
| Product category | Principal protection type | Current commercial relevance |
|---|---|---|
| EpiPen | Auto-injector architecture, cartridge and delivery mechanisms | Legacy patents have largely expired or lost exclusivity value |
| Auvi-Q | Electronic voice guidance, compact injector design, operating controls | Device and implementation patents may remain relevant by product and jurisdiction |
| Generic auto-injectors | Product-specific device and formulation claims | Regulatory design-around and manufacturing execution matter more than molecule patents |
| Hospital epinephrine injection | Active ingredient and conventional injectable formulation | Little meaningful composition-of-matter protection |
| Prefilled epinephrine syringes | Syringe, container, stability, and packaging claims | Potential device and manufacturing barriers |
Patent protection for an epinephrine auto-injector must be assessed at the product level. A single product may have several U.S. patents, continuation applications, foreign counterparts, and FDA-listed patents. Patent expiration dates can differ from regulatory exclusivity dates because of patent-term adjustment, patent-term extension, terminal disclaimers, and pediatric exclusivity.
A definitive current patent count requires a product-specific review of FDA Orange Book records, USPTO records, and litigation dockets. There is no single patent estate covering all epinephrine products.
What patents protect procaine hydrochloride?
Procaine hydrochloride has no commercially significant composition-of-matter patent estate. The active ingredient is an established generic anesthetic. Potential rights may cover:
- Concentration or pH adjustments.
- Preservative systems.
- Injectable packaging.
- Stability improvements.
- Combination products.
- Specific dosing or procedural methods.
These rights generally have limited economic scope because physicians can substitute other local anesthetics and manufacturers can market conventional procaine hydrochloride products through established generic pathways. The main barriers are manufacturing compliance, sterile-fill capacity, quality systems, and reliable supply of injectable products.
When do epinephrine and procaine hydrochloride lose exclusivity?
Epinephrine lost active-ingredient exclusivity decades ago. For current auto-injector products, commercial exclusivity is determined by a combination of:
- Device patents.
- FDA regulatory exclusivity.
- Design complexity.
- Manufacturing capacity.
- Brand recognition.
- Distribution and reimbursement contracts.
EpiPen’s original market position was therefore not protected by a surviving epinephrine molecule patent. Its economic moat depended on delivery-device know-how, first-mover scale, physician familiarity, and market access.
Procaine hydrochloride has already lost conventional pharmaceutical exclusivity. Generic competition is legally permissible, subject to FDA approval, manufacturing compliance, and product availability. No major pending loss-of-exclusivity event is expected to materially change the procaine market.
Exclusivity timeline
| Period | Epinephrine | Procaine hydrochloride |
|---|---|---|
| Historical period | Active ingredient and early formulations became generic | Active ingredient became generic |
| 2000s-2010s | Auto-injector device protection and brand concentration drove pricing | Mature generic market |
| 2015-2017 | EpiPen pricing controversy increased generic and policy pressure | Limited commercial change |
| 2018-present | Generic auto-injectors and alternative devices expanded | Demand remains specialized and price-sensitive |
| Forward outlook | Device-based competition and supply reliability remain decisive | Low patent risk; limited growth |
What is the Orange Book status of epinephrine and procaine hydrochloride?
The Orange Book lists approved drug products and, where applicable, patents and exclusivity information. For epinephrine, Orange Book analysis is most relevant to branded or device-based auto-injector NDAs. Patent listings may relate to the drug-device combination rather than the epinephrine molecule.
For procaine hydrochloride, Orange Book value is limited because the market is dominated by generic injectable products. ANDA products typically rely on reference-product approval pathways and do not create a branded patent barrier comparable to a novel drug.
Orange Book status should not be treated as a complete freedom-to-operate analysis. Device patents, manufacturing patents, continuation claims, and patents not listed for FDA purposes can still affect launch risk. (FDA, 2024b)
Which companies are challenging epinephrine exclusivity?
Epinephrine competition comes from generic manufacturers and alternative branded-device developers rather than from traditional Paragraph IV challenges to a novel molecule.
Key market participants include:
- Viatris, through the EpiPen franchise and authorized-generic channels.
- Teva Pharmaceuticals, through generic epinephrine auto-injectors.
- Kaleo, through Auvi-Q.
- Adamis Pharmaceuticals and related commercial partners, historically associated with alternative auto-injector development.
- Sanofi, which previously commercialized Auvi-Q in the U.S. before rights returned to Kaleo.
- Hospital injectable suppliers, including major generic sterile-injectable manufacturers.
What Paragraph IV risks exist?
Paragraph IV litigation risk is product-specific. A generic auto-injector applicant may certify against listed patents covering the reference product, device, formulation, or use. Litigation can delay approval or launch under the Hatch-Waxman framework.
The risk is lower for conventional epinephrine injection because the active ingredient is mature and competing products have limited formulation differentiation. The risk is higher for complex auto-injectors because device patents and equivalence requirements can create multiple points of dispute.
For procaine hydrochloride, Paragraph IV exposure is generally low. The market’s principal risks are supply interruption, sterile-manufacturing failure, and product discontinuation rather than patent litigation.
What patent litigation and settlement agreements affect these markets?
The major historical legal disputes in epinephrine have concerned auto-injector pricing, device competition, patent assertions, regulatory substitution, and access. EpiPen became the focus of congressional and public scrutiny after substantial price increases during the 2010s. The commercial response included authorized generics, competing auto-injectors, and increased payer pressure.
A current investment-grade review must separate:
- Patent litigation.
- Antitrust and pricing investigations.
- FDA approval disputes.
- Product-liability cases.
- Manufacturing and recall actions.
These proceedings have different effects on revenue and launch timing. A patent settlement can delay generic entry, while a recall or shortage can quickly transfer market share without changing patent rights.
No broad, durable settlement framework controls the entire epinephrine auto-injector market. Procaine hydrochloride has little visible strategic litigation because the product is old, inexpensive, and commercially fragmented.
How strong is the patent estate for epinephrine compared with procaine hydrochloride?
| Factor | Epinephrine auto-injectors | Procaine hydrochloride injection |
|---|---|---|
| Active-ingredient patent strength | Very low | None of practical significance |
| Device patent strength | Moderate, product-specific | Minimal |
| Formulation patent strength | Low to moderate | Low |
| Regulatory complexity | High for auto-injectors | Moderate for sterile injectables |
| Manufacturing barriers | High for reliable device assembly | Moderate to high for sterile filling |
| Substitution risk | Moderate | High |
| Litigation risk | Moderate for device products | Low |
| Revenue concentration | High in branded devices | Low |
| Generic entry risk | Material but execution-dependent | Already established |
Epinephrine’s strongest defensibility is operational. A manufacturer must demonstrate dose accuracy, usability, reliability, human factors performance, container compatibility, and consistent device assembly. Those requirements can delay competitors even when patent protection is weak.
What formulations are protected by epinephrine patents?
The most commercially relevant epinephrine formulation claims concern:
- Concentration and delivered dose.
- Solution stability.
- Oxygen and light protection.
- Cartridge and syringe compatibility.
- Needle deployment.
- Automatic injection force.
- Dose completion and lockout mechanisms.
- Electronic instructions and user feedback.
A formulation that is chemically equivalent to a generic epinephrine solution may still require a differentiated container, device, or manufacturing process. The regulatory question is whether the full combination is therapeutically equivalent and reliable, not whether the active ingredient is novel.
Procaine hydrochloride formulations are more conventional. Potential differentiation may involve preservative-free presentations, pH control, concentration, container closure, or compatibility with specific procedures. These features rarely create a durable premium without clinical or procurement advantages.
What is the financial trajectory for epinephrine?
Epinephrine has a two-tier financial structure.
The auto-injector market can support substantial revenue because of:
- High perceived value during emergencies.
- Multiple-device household use.
- School, workplace, ambulance, and public-access programs.
- Brand recognition.
- Replacement demand caused by expiration.
- Reimbursement and formulary contracts.
The market also faces pressure from:
- Generic substitution.
- Public scrutiny of price increases.
- Payer negotiations.
- Expiring devices and wastage.
- Shortages and recalls.
- Lower-cost authorized generics.
- Consumer sensitivity to out-of-pocket prices.
Mylan’s EpiPen franchise generated more than $1 billion in annual sales at its peak before generic competition and pricing pressure reduced its contribution. The exact current revenue contribution is not separately disclosed in all public filings because epinephrine products are often reported within broader North American or commercial segments. (Viatris, 2024)
Hospital epinephrine injection is a high-volume, low-margin market. Revenue depends on contract awards, shortages, manufacturing reliability, and hospital purchasing groups. Volume can increase during supply disruptions, but pricing gains are usually constrained by generic procurement.
Generic launch scenarios for epinephrine
| Scenario | Market effect | Financial effect |
|---|---|---|
| One reliable generic auto-injector | Moderate price reduction | Brand share declines, but premium remains |
| Several reliable generics | Significant price compression | Revenue shifts toward volume and contracting |
| Device recall or shortage | Temporary share reversal | Reliable suppliers gain pricing and volume |
| New compact or voice-guided device | Segment expansion | Premium pricing possible with payer acceptance |
| Broad public-access programs | Unit growth | Lower prices may be offset by higher volume |
What is the financial trajectory for procaine hydrochloride?
Procaine hydrochloride has a low-value financial profile. Its use has declined relative to lidocaine and other local anesthetics because of shorter duration, less favorable contemporary practice patterns, and broad availability of alternatives.
Revenue is driven by:
- Dental and minor-procedure use.
- Regional or local anesthesia in selected settings.
- Institutional purchasing.
- Product availability during shortages of substitute anesthetics.
- Low-cost generic procurement.
The market has limited capacity for sustained price expansion. A manufacturer can generate value through reliable sterile production, low-cost manufacturing, and contract supply, but a branded premium is difficult to sustain.
The principal commercial risk is discontinuation. If only one or two suppliers remain, a manufacturing event can create temporary scarcity. That scarcity can improve short-term pricing but usually does not create durable market growth.
How do epinephrine and procaine hydrochloride compare commercially?
| Metric | Epinephrine | Procaine hydrochloride |
|---|---|---|
| Core use | Emergency treatment of anaphylaxis and cardiovascular events | Local anesthesia |
| Growth driver | Auto-injector adoption, public access, emergency preparedness | Stable niche use |
| Pricing power | Moderate in branded devices; low in hospital injectables | Low |
| Patent value | Device and formulation dependent | Negligible |
| Generic threat | Significant | Structural and longstanding |
| Regulatory barrier | High for auto-injectors | Lower, but sterile manufacturing matters |
| Market concentration | Higher in auto-injectors | Fragmented |
| Revenue visibility | Better for branded devices | Limited |
| Investment profile | Execution and access driven | Supply and cost driven |
What generic entry risks exist for epinephrine and procaine hydrochloride?
Epinephrine generic-entry risk is highest in auto-injectors. Competitors must address device equivalence, usability, dose delivery, labeling, packaging, and supply scale. An approved generic can still struggle commercially if it lacks payer coverage, pharmacy distribution, or reliable inventory.
Procaine hydrochloride faces little future generic-entry risk because the market is already generic. New entrants would mainly increase price competition or provide a backup source during shortages.
What geographic coverage and manufacturing barriers matter?
Epinephrine auto-injector manufacturers need regional regulatory approvals, local pharmacovigilance systems, qualified device suppliers, and reliable combination-product manufacturing. U.S. and European requirements can differ in labeling, device conformity, human factors evidence, and substitution rules.
Procaine hydrochloride has broader geographic generic availability, but sterile manufacturing capacity is concentrated. A quality failure at a major injectable supplier can affect multiple countries. Manufacturing barriers include aseptic processing, container closure integrity, particulate control, validated sterilization, and inspection compliance.
Key Takeaways
- Epinephrine’s molecule is generic; commercial protection resides in auto-injector devices, regulatory execution, manufacturing, and distribution.
- EpiPen’s historical billion-dollar revenue scale was driven by market concentration and device economics, not surviving molecule patents.
- Generic epinephrine auto-injectors create continuing price and share pressure, but reliable supply remains a competitive advantage.
- Procaine hydrochloride has no meaningful modern composition-of-matter patent estate and limited commercial growth potential.
- Procaine’s principal risks are sterile-manufacturing disruption, supplier exits, and substitution by lidocaine or other anesthetics.
- Patent litigation is materially more relevant to epinephrine auto-injectors than to procaine hydrochloride.
- Neither market should be valued from active-ingredient patent life alone.
FAQs
Is epinephrine still protected by patents?
The epinephrine molecule is not protected by meaningful active-ingredient patents. Product-specific device, formulation, and manufacturing patents may still affect individual auto-injectors.
Is procaine hydrochloride still under patent?
Procaine hydrochloride is a mature generic active ingredient with no commercially significant composition-of-matter patent protection.
Can a generic EpiPen launch without patent litigation?
Yes. A generic applicant may launch after resolving listed patents, prevailing in litigation, reaching a settlement, or determining that no blocking patent remains. Device-specific patents can still affect timing.
Which drug has greater investment potential, epinephrine or procaine hydrochloride?
Epinephrine has greater investment potential because auto-injectors support higher revenue, recurring replacement demand, and product differentiation. Procaine hydrochloride is mainly a low-margin supply business.
What is the main barrier to competing with EpiPen?
The main barrier is integrated device and supply-chain execution. Dose accuracy, human factors, manufacturing scale, pharmacy distribution, payer access, and reliable inventory are more important than epinephrine molecule patents.
References
- U.S. Food and Drug Administration. (2024a). Epinephrine auto-injector products and generic drug approvals. https://www.fda.gov
- U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024c). Drug shortages: Epinephrine injection and related products. https://www.accessdata.fda.gov/scripts/drugshortages/
- Viatris Inc. (2024). Annual report for fiscal year 2023. https://www.viatris.com
- U.S. Government Accountability Office. (2017). Drug industry: Drug pricing and the EpiPen market. https://www.gao.gov
More… ↓
